- Associated Press - Tuesday, November 24, 2015

OXFORD, Miss. (AP) - A privately held biotechnology company will conduct a clinical trial of a compound based on research conducted at the University of Mississippi and ElSohly Laboratories.

Hapten Sciences Inc. will soon begin a Phase I clinical trial of the compound which could prevent contact dermatitis due to exposure to poison ivy, oak and sumac, The Oxford Eagle (https://bit.ly/1P1TKDD) reports.

The company obtained license for the technology from the university and will now be able to initiate dosing of the compound to healthy volunteers.

“Since company inception, Hapten Sciences has pursued an aggressive and efficient development timeline,” said Raymond J. Hage Jr., Hapten Sciences chief executive officer.

He said the company is enthusiastic to begin development of a compound that can prevent associated medical treatments and lost time at work.

The technology was initially developed by Mahmoud ElSohly, research professor in the UM School of Pharmacy’s Research Institute of Pharmaceutical Sciences and professor of pharmaceutics; Khalid Ashfaq, principal research scientist II at the School of Pharmacy; and Waseem Gul, associate director of research at ElSohly Laboratories.

“This is a very exciting development in the potential prevention of a very serious allergic reaction,” ElSohly said.

The studies are slated for 2016. The trail will be a randomized, double-blind, placebo-controlled study of single ascending doses. It is intended to determine the safety and tolerability of the compound.


Information from: Oxford Eagle, https://www.oxfordeagle.com

Copyright © 2018 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide